The old and new therapeutic approaches to the treatment of giardiasis: Where are we?

Haendel GNO Busatti1, Joseph FG Santos2, Maria A Gomes11Departmento de Parasitologia, ICB, Universidade Federal de Minas Gerais, Belo Horizonte, Brasil; 2Hospital Santa Casa de Misericórdia de Belo Horizonte, Minas Gerais, BrasilAbstract: Giardia lamblia is the causative agent of giar...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Haendel GNO Busatti, Joseph FG Santos, Maria A Gomes
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2009
Materias:
Acceso en línea:https://doaj.org/article/abc145b369614188852be0c27c4bba9c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Haendel GNO Busatti1, Joseph FG Santos2, Maria A Gomes11Departmento de Parasitologia, ICB, Universidade Federal de Minas Gerais, Belo Horizonte, Brasil; 2Hospital Santa Casa de Misericórdia de Belo Horizonte, Minas Gerais, BrasilAbstract: Giardia lamblia is the causative agent of giardiasis, one of the most common parasitic infections of the human intestinal tract. This disease most frequently affects children causing abdominal pain, nausea, vomiting, acute or chronic diarrhea, and malabsorption syndrome. In undernourished children, giardiasis is a determining factor in retarded physical and mental development. Antigiardial chemotherapy focuses on the trophozoite stage. Metronidazole and other nitroimidazoles have been used for decades as the therapy of choice against giardiasis. In recent years many other drugs have been proposed for the treatment of giardiasis. Therefore, several synthetic and natural substances have been tested in search of new giardicidal compounds. This study is a review of drugs used in in vitro and in vivo tests, and also drugs tested in clinical trials (nonrandomized and randomized).Keywords: Giardia lamblia; treatment; new drugs